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S100B is a calcium binding peptide produced predominantly by astroglial cells in the central
nervous system. S100B paradoxically has neurotrophic and apoptotic effects, dependent
on extracellular concentration. This study investigated the relationship between serum
S100B levels and neuropsychological performance across a range of cognitive domains in
healthy older aged adults. A cohort of 219 participants between the ages of 43 and 84 years
(141 female) were recruited. Subjects provided a fasting blood sample for S100B mea-
surement (Mean=0.24 ng/mL, SD=0.14) and completed a battery of neuropsychological
tests. S100B concentrations (both with and without the covariates of age and sex) were
positively associated with the following measures of cognitive performance: digit-symbol
coding, Stroop test, and measures of verbal ability. The results from this study show that
serum S100B is positively associated with better cognitive performance in healthy older
adults.
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INTRODUCTION
In 1965, Moore described a mixture of low molecular weight
proteins belonging to the calcium-sensor-binding-proteins super-
family (Moore, 1965). Indicative of their solubility in saturated
ammonium sulfate solution, S100A is a heterodimer synthesized
in muscles and neurons, whereas S100B is homodimer produced
by neural astroglial and Schwann cells (Heizmann, 2002). The bio-
logical effects of S100 proteins are functional following binding
of ionized calcium, which induces a conformational change and
exposure of functional hydrophobic residues (Smith et al., 1996).
Key functional intracellular effects of S100B are purported to
be in regulation of cell proliferation and cytoskeletal structure
(Sorci et al., 1998). Extracellular effects at nanomolar concentra-
tions of S100B have potent neurotrophic and gliotrophic actions,
principally by ameliorating the effects of altered redox states that
occur as a consequence of mitochondrial dysfunction (Selinfre-
und et al., 1991; Donato, 2001). In addition to its significance
in central nervous system (CNS) development, S100B may be
restorative following brain injury (Ellis et al., 2007). However,
paradoxical biological effects of S100B are reported at micromolar
levels in extracellular fluids such as plasma or cerebrospinal fluid
(CSF). In vitro studies have identified that at these higher con-
centrations extracellular S100B binds to the receptor for advanced
glycation end products, stimulating the caspase pathway (a pivotal
mediator for programed cell death, necrosis, and inflammation)
(Huttunen et al., 1999). At these concentrations, cytokine produc-
tion is enhanced resulting in increased production of potentially
cytotoxic amounts of reactive oxygen species and nitric oxide
(Bianchi et al., 2007). It is these properties of S100B that have led
to the hypothesis that elevated S100B contributes to neurovascular
inflammatory disorders.
The demonstrated paracrine and autocrine effects of S100B
on neurons and glia and the neural-to-plasma kinetic gradient of
S100B has raised the possibility that S100B could be a useful blood
biomarker for disorders of the CNS. The relatively short half-
life of plasma S100B (∼30 min) and renal clearance (2 h) would
support the contention that a chronic change in serum S100B con-
centration may reflect homeostatic alterations of neural integrity
(Jonsson et al.,2000).Yardan et al. (2011) provide an elegant review
of S100B in the context of its putative function in individuals
who have experienced head trauma, neurovascular degenerative
conditions, or psychological disorders.
Alzheimer’s disease (AD), the most common neurodegenera-
tive disorder, is clinically characterized by a progressive loss of
cognitive functioning that typically starts with a decline in episodic
memory (Backman et al., 2004). In AD and in subjects with
frontotemporal lobe dementia, S100B levels were reported to be
significantly increased compared to healthy controls (Green et al.,
1997; Peskind et al., 2001). However,Yardan et al. (2011) suggested
that S100B’s abundance and distribution and its putative role in the
onset and progression of AD could notionally change over the time
course of the disease. Chronically suppressed levels of extracellular
S100B may be detrimental to neuronal function and be implicated
in AD onset. However, during periods of heightened inflammation
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or more active plaque formation, greater S100B concentration
in serum might be expected. The latter could be considered an
injury response that provides benefit (at lower concentration)
or exacerbates inflammatory sequelae (at higher concentrations).
Thereafter, at the end-stages of AD, normal or perhaps decreased
synthesis and secretion of S100B may occur. This was reported
by Peskind et al. (2001) who found that S100B concentrations
were increased in mild-to-moderate AD subjects but not in the
advanced stage of the disease. Consistent with a transient func-
tional role of S100B in neurodegenerative disease, Schaf et al.
(2005) reported a correlation of S100B with the Hoehn and Yahr
stage of Parkinson’s disease, but no difference per se when S100B
was measured in Parkinson’s disease subjects versus controls. Fur-
thermore, Nooijen et al. (1997) found no significant difference in
concentration of S100B in various types of dementia apart from in
subjects with Creutzfeldt–Jakob disease. However, an association
with disease onset or progression was not considered in this study.
Cognition (as per complex biological phenomena in general)
is a multifactorial entity that reflects the composite domains of
perceptual speed, primary memory, secondary memory, verbal
ability, linguistic abilities, and executive functioning. In subjects
with mild-cognitive impairment, secondary memory (episodic
memory) deficits and (to a lesser extent) perceptual speed and
executive functioning deficits appear to be most indicative of
subjects who will progress to AD (Weintraub et al., 2012). The
fractionation of different elements of cognition assessed against
biomarkers could provide a powerful approach to modeling the
putative relationship(s) between cognitive outcomes and regula-
tory biological factors in the aging process (specifically concerning
biological risk factors for pro-dromal AD). In this study, we there-
fore used a battery of tests that specifically evaluated each of the
aforementioned cognitive domains, and we explored if there was
a statistical association between cognitive test performance and
serum S100B concentration. The hypothesis was that, in gener-
ally healthy subjects, the neurotrophic properties of S100B would
generally correlate positively with cognitive capacity.
MATERIALS AND METHODS
PARTICIPANTS
The study was approved by the Curtin University Human Research
Ethics Committee (HR97/2011). A total of 250 participants (96
males, 154 females) over the age of 40 (range= 43–84 years) were
recruited. All participants provided written consent and com-
pleted a medical history and medications questionnaire and were
interviewed to confirm the information provided. Exclusion cri-
teria for the study were: major surgery or a clinical event within
6 months; current diagnosis with a psychiatric disorder or tak-
ing psychotropic medications; hemophilia; cancer/chemotherapy;
head injury within 5 years; diagnosis with HIV. Furthermore, par-
ticipants were excluded from the statistical analyses if any of
the following obtained: renal impairment; liver dysfunction; Mini
Mental State Examination (MMSE) score <24.
SERUM S100B
Peripheral venous samples were collected into serum separator
Vacutainer™ tubes (Becton Dickinson, Franklin Lakes, NJ, USA)
following an overnight fast for at least 8 h. Samples were allowed
to clot for 30 min and serum was isolated and stored at −80°C
following low-speed centrifugation. Serum S100B was measured
using a commercially available ELISA kit (Cosmo Bio, Japan) with
an interassay coefficient of variance of 4.82–9.20%. The sensi-
tivity and dynamic range of the S100B assay is 0.078–5 ng/mL
(7–470 pmol/L).
NEUROPSYCHOLOGICAL MEASURES
The cognitive tests were administered by trained staff under super-
vision of a registered clinical neuropsychologist. Tests were chosen
based upon their widespread use, reliability, and validity, and to
cover the principal domains of cognitive performance affected in
age-related cognitive decline. The performance tasks included the
MMSE (Folstein et al., 1975), Rey Auditory Verbal Learning Test
(RAVLT) (Lezak et al., 2004), Delis–Kaplan Executive Function
System (D–KEFS) verbal fluency subtests (Delis et al., 2001), 60-
item Boston Naming Test (BNT) (Saxton et al., 2000), National
Adult Reading Test (NART) (Nelson and Willison, 1991), Digit
Span and Digit-Symbol Coding subtests from the Wechsler Adult
Intelligence Scale-Third edition (WAIS-III) (Wechsler and Scale,
1997; Strauss et al., 2006), and the Stroop test (Victoria version)
(Strauss et al., 2006).
STATISTICAL ANALYSIS
The relationship between serum S100B and cognitive performance
was considered using a nested domain Bayesian mixed-model
(Thurston et al., 2009). The nested domain model increases power
by pooling outcome estimates from within a cognitive domain
toward each other, reducing Type S (sign) and Type M (magnitude)
errors through shrinkage toward common estimates (Gelman
et al., 2012).
The principal domains assessed were D1 – verbal ability [BNT
and D–KEFS fluency (letter fluency, category fluency, and cate-
gory switching)]; D2 – Stroop [Dots, Words, and Colors response
time, and interference (Colors/Dots) ratio]; D3 – secondary mem-
ory [total items recalled across learning trial, items recalled from
interference list, short delay free recall, long delay free recall, recog-
nition “hits,” short delay forgetting score (learning trial 5 – short
delay), and long delay forgetting score (learning trial 5 – long
delay)]; D4 – primary memory (digits forward and digits back-
wards); and D5 – perceptual speed (digit-symbol coding). The
outcome measurements to be nested within each domain were
chosen a priori. An objective Bayesian approach to setting the pri-
ors was used, that is all priors could be described as being weakly
informative, or uninformative for the scale of the data. Priors for
the overarching coefficients were described by a normal distribu-
tion with a mean= 0 and SD= 100. The remaining coefficients for
the outcomes and domains were described as being derived from
a normal distribution centered on 0 and a SD estimated from a
half-Cauchy distribution centered on 0, and scale set to 25 (Gel-
man, 2006). Outcome level errors were modeled as being derived
from a t -distribution to render the analysis robust (Lange et al.,
1989; Kruschke, 2012). The prior for the SD for each outcome was
described by a uniform distribution between 0 and 100 and the
degrees of freedom parameter was estimated from the inverse of
a uniform distribution with lower and upper limits of 0.001 and
0.5. A large estimate for the degrees of freedom parameter indicates
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that the residuals can be described by normal distribution, while a
smaller degrees of freedom parameter indicates that the data have
fatter tails and data points in this region are appropriately down-
weighted. Each variable was scaled to a mean of 0 and a SD of 1. If a
smaller score on any neuropsychological measure indicated “bet-
ter” performance, the score was inverted. After 5000 adaptation
steps and 50,000 burn-in steps, a total of 50,000 Markov Chain
Monte Carlo (MCMC) samples (thinned every tenth step) were
saved across three chains for the final parameter estimates. Con-
vergence was confirmed by examining plots of the posterior and
using the Gelman–Rubin diagnostic (Gelman and Rubin, 1992).
All posterior distributions used for inference had a minimal effec-
tive sample size of at least 1000 (usually ∼10,000). The means
±95% highest density intervals (HDI) of the posterior distribu-
tion were used to describe the credibility interval for each of the
parameter estimates (Kruschke, 2012). All statistical analyses were
conducted in R version 3.0.0 using the “rjags” package (Plummer,
2013).
RESULTS
RELATIONSHIP BETWEEN S100B AND COVARIATES AGE AND SEX
A total of 219 participants met the key inclusion criteria for
this study. The mean age of the cohort was ∼65 years. All
included participants had an MMSE scores>25. The mean serum
S100B concentration was 0.24 ng/mL and normally distributed
for the cohort; however, the range was substantial (Table 1).
The covariates of age (slope=−0.001 ng/mL/year, HDI=−0.004,
0.002) and sex (contrast F-M=−0.02 ng/mL, HDI=−0.06, 0.02)
were not substantially associated with S100B. By contrast, NART
errors were negatively associated with S100B concentrations
(slope=−0.004 ng/mL/error, 95% HDI=−0.007,−0.0008).
RELATIONSHIP BETWEEN S100B AND NEUROPSYCHOLOGICAL
PERFORMANCE
Figure 1 presents the standardized slope coefficients (mean±80%,
95% HDI) for the association between S100B and neuropsycho-
logical performance both with and without the covariates of age,
sex, and NART. S100B both with and without the covariates of age
and sex was positively associated with performance on a range of
neuropsychological measures. In the models that excluded covari-
ates, S100B was positively associated with perceptual speed (D5),
Stroop (D2), and verbal ability (D1). While the credible inter-
vals for the primary memory (D4) and secondary memory (D3)
domains included 0, their mean effect sizes were similar to the
Stroop (D2) and verbal ability (D1) domains. Including the covari-
ates age and sex did not appreciably alter the relationship between
S100B and cognitive performance. By contrast, the addition of
NART scores modestly reduced the mean estimates and associ-
ated confidence intervals across the range of neuropsychological
measures used.
DISCUSSION
Serum S100B has been suggested to be a candidate marker of CNS
injury because its concentration is increased after head trauma
and in several neurodegenerative conditions (Sen and Belli, 2007).
In these circumstances, heightened overproduction of S100B may
amplify inflammatory processes and exacerbate cell stress as a
Table 1 | Measures of age, S100B concentration and MMSE scores and
neuropsychological measures for the study cohort of 219 participants.
Mean SD Range
Sex (F | M) 141 | 78
Age 64.9 7.3 43.6–84.2
S100B (ng/mL) 0.24 0.14 0.08–0.62
MMSE 28.7 1.3 25–30
NART error score 14.1 6.6 3–39
NEUROPSYCHOLOGICAL MEASURES
Perceptual speed
Digit-symbol coding 64.6 13.9 23–95
Primary memory
Digits forward 6.8 2.0 6–16
Digits backward 10.4 2.2 3–18
Secondary memory
RAVLT sum of trials 1–5 44.5 9.6 16–64
RAVLT interference list 5.1 1.9 1–11
RAVLT short delay recall 9.1 3.1 0–15
RAVLT long delay recall 9.1 3.1 0–15
RAVLT recognition ‘Hits’ 13.4 1.9 0–15
RAVLT decay T5 – short delay 2.1 2.0 −3–11
RAVLT ‘decay’ T7 – short delay 2.2 2.0 −3–8
Stroop
Stroop words time 18.5 7.3 11–101
Stroop dots time 13.9 3.5 7–36
Stroop colors time 29.9 10.1 14–80
Stroop interference (C/D) 2.2 0.66 0.8–4.8
Verbal ability
D–KEFS letter fluency 40.9 11.8 7–71
D–KEFS category fluency 44.5 8.9 23–69
D–KEFS switching total 13.6 2.9 4–21
Boston naming test 56.3 4.2 26–60
consequence of altered redox state. An alternative interpreta-
tion is that elevated serum S100B is a consequence of amplified
inflammation and cell stress, as several lines of evidence show
significant positive trophic effects of S100B consistent with a neu-
roprotective function. This study explored for the first time the
relationship between serum S100B and neuropsychological test
performance across a range of cognitive domains in a relatively
health cohort of older aged participants. Our analyses indicated
that this study cohort manifested serum S100B concentrations
which have been reported to support cell function and integrity in
cell culture studies (i.e., <nanomolar range). No participant had
serum S100B concentrations considered potentially indicative of
CNS injury (i.e., micromolar range). Utilizing a nested cognitive
domain model to explore the hypothesis of an association between
cognitive capacity and serum S100B, the data indicates a positive
association with all cognitive domains and in particular for per-
ceptual speed, Stroop, and verbal ability. Adjustments for NART,
but not age and gender, had a modest attenuating effect on the
associations observed.
The largest effect size with respect to the association between
cognitive performance and S100B was on the digit-symbol
coding measure, reflecting perceptual, and motor speed. Similarly,
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FIGURE 1 | Standardized slope coefficients (mean ±80%, 95% HDI) for the association between S100B and neuropsychological performance; both
with and without the covariates of age, sex, and premorbid functioning.
performances on other speeded tasks (Stroop and verbal ability)
were positively associated with serum S100B. The finding may
indicate a beneficial association between S100B and “on line”
speeded tasks. This is a potentially important finding, as “speed”
has been considered a fundamental component of age-related CNS
functional integrity (Salthouse, 1996). However, given that there
are only very modest differences between the mean parameter esti-
mates for the different cognitive domains that were evaluated in
this study, the apparent selectivity of S100B for the speeded tasks
may be more reflective of the psychometric properties of the tasks.
For example, many of the secondary memory measures (which are
derived from the RAVLT) only have a range of 15 discrete possi-
bility outcomes, compared to the more continuous nature of the
Stroop test and the larger range of possible scores on the Digit-
Symbol Coding test. Therefore, an alternative hypothesis to be
explored is whether S100B is selectively associated with particular
cognitive domain(s) (for example, if the functional capacity of spe-
cific brain regions are associated with levels of S100B), or whether
these concentrations are associated with a global enhancement of
cognitive performance (as might be expected if cognitive process-
ing were generally “faster” when higher concentrations of S100B
are present within the healthy physiological range).
There has been significant interest in S100B as a potential
marker of CNS trauma, distress, or pathological disturbances, and
in this context S100B is described as an acute-phase response pro-
tein (Sen and Belli, 2007). In contrast, non-injurious and chronic
levels of serum S100B would presumably represent constitutive
rates of biosynthesis and metabolism. For this study, participants
were currently functioning within the“healthy”range and individ-
uals with head trauma, or other conditions known to significantly
influence serum S100B concentration were excluded. Therefore, it
appears reasonable to assume that S100B was not indexing CNS
dysfunction.
Several lines of evidence support an important role for S100B
in CNS development. Heightened S100B in response to stressors
may be indicative of insult severity, although in many instances it
has been suggested to be causally related to pathological sequelae.
Intraventricular infusion of low concentrations of S100B induces

























































Lam et al. Cognitive performance and serum S100B
neurogenesis within the hippocampus in a traumatic brain injury
model, and this was associated with enhanced cognitive function
(Kleindienst et al., 2005).
S100B is mainly found in astroglial and Schwann cells and is
enriched in CSF relative to blood. Many studies have therefore
suggested that elevated serum S100B could be a useful surro-
gate marker of blood-brain leakage (Marchi et al., 2003); indeed,
this proposal is supported in clinical and animal head trauma
findings. However, other sources of serum S100B could include
adipocytes, chondrocytes, lymphocytes, bone marrow cells, and
melanocytes, with clearance occurring predominantly via renal
excretion. Based on the exclusion criteria indicated in this study
(no recent head trauma, frank neurological disorder, or renal dys-
function), serum S100B homeostasis was evaluated in a “healthy”
physiological context rather than in a neuropathological context,
with the evidence suggesting positive associations with cognition
in healthy participants.
The cross-sectional study design that was used unfortunately
does not permit delineation of possible casual mechanisms with
respect to the association between serum S100B and cognitive
performance. Possible effects of S100B relevant to cognition may
include improved redox state and cell function; suppression of
neurovascular inflammation; enhanced conduction and transmis-
sion of nerve impulses (putatively of marked relevance given the
findings on “speeded” cognitive tasks noted in this study); promo-
tion of cell growth and/or differentiation or enhanced cytoskeletal
structure.
Future studies to investigate the relationship of serum
S100B levels and cognitive/neurological functions under
stress/pathological conditions may be particularly warranted. The
body of evidence to date suggests that S100B may be an acute-
phase response-to-injury protein that confers positive trophic and
functional effects of the neurovascular unit. However, S100B is
not normally considered as a chronic modulator of neurovas-
cular function. Evidence consistent with the latter may provide
therapeutic opportunities particularly in the pre- and pro-dromal
phase of neurodegenerative conditions such as AD. Realization
of the clinical translatability will however require a comprehen-
sive understanding of S100B metabolism, kinetics, and molecu-
lar mechanisms. Common to these proposed functional effects
is binding of S100B to ionized calcium, which as a conse-
quence exposes hydrophobic residues (thereby enabling S100B to
interact with other proteins and thus exert a biological effect).
Possible synergistic effects of S100B and calcium metabolism
on cognition may therefore be of particular interest in future
studies.
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